Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | NAT1 | P18440 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618043 | 0.82 | TRIM24 (0.46) | ERN1TRIM24TRIM33CA12CA1 | |
| SCHEMBL6618412 | 0.81 | ERN1 (0.47) | ERN1 | |
| SCHEMBL6622832 | 0.73 | ALDH1A1 (0.34) | ERN1TRIM24TRIM33KIF11 | |
| SCHEMBL26704110 | 0.71 | TRIM24 (0.50) | ERN1TRIM24TRIM33DYRK1ADYRK2 | |
| SCHEMBL6619511 | 0.70 | HSD17B1 (0.59) | ERN1TRIM24TRIM33DYRK1ADYRK2 | |
| SCHEMBL13840638 | 0.70 | CA2 (0.47) | CA1CA2AKR1C2AKR1C1 | |
| SCHEMBL6623060 | 0.70 | TRIM24 (0.36) | TRIM24TRIM33CA12CA1CA2 | |
| SCHEMBL15229652 | 0.69 | TRIM24 (0.51) | ERN1TRIM24TRIM33DYRK1ADYRK2 | |
| SCHEMBL5735574 | 0.68 | TRIM24 (0.54) | ERN1TRIM24TRIM33DYRK1ADYRK2 | |
| SCHEMBL26704175 | 0.68 | KIF11 (0.73) | TRIM24TRIM33KIF11CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | ERN1 3033/4885TRIM24 2930/4885TRIM33 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.